Another year has passed, even more challenging than the previous one, where the Cough & Cold demand of products has significantly increased in an unpredictable economic context that caused unforeseeable pressures on supply chains, impacting our daily costs and regular processes.

More than ever, flexibility has been our key pillar, as day by day we had to redefine our plans and strategy according to our client’s needs in a complex and constantly changing environment.

I would like to take a moment to recognize our team and shareholders for all the accomplishments made during the year, which couldn’t be possible without their commitment, dedication and efforts.

This year we have made significant progress in growing our pipeline with 5 new developments and we are extremely excited to continue our research and innovation to develop future products within 2023.

This year we have also expanded our activity to new territories where Geiser Pharma was not present yet, such as Colombia, China and Vietnam and we have reinforced our expansion plans to Canada and Brazil for 2023.

This could not have been possible without the collaboration and trust of our clients and partners, that has also enabled us to sign 35 new contracts.

On behalf of Geiser’s team and Board of Directors, I sincerely thank you for your continued support despite all the difficulties and I am confident that we will be able to reach our goals and even exceed our challenging expectations for the upcoming exciting years.